Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

Clinical trial NCT04335292 · RECRUITING

Trial details

NCT number: NCT04335292
Sponsor: Mark Vincent
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer

Start date: 2021-01-06
Primary completion: 2026-06-01
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.